0
0
TUCSON, AZ – Researchers at the University of Arizona Health Sciences have discovered that terpenes, aromatic compounds found in the Cannabis sativa plant, may offer a new avenue for treating fibromyalgia and post-surgical pain. The findings, published in the journal Pharmacological Reports, suggest that these compounds could provide significant pain relief without the psychoactive effects associated with THC.
The study, led by Dr. John Streicher, a professor in the U of A College of Medicine—Tucson’s Department of Pharmacology, builds upon previous research demonstrating the pain-relieving properties of terpenes in models of inflammation and chemotherapy-induced neuropathic pain.
“Our research is showing that terpenes are not a good option for reducing acute pain resulting from an injury, such as stubbing your toe or touching a hot stove; however, we are seeing significant reductions in pain when terpenes are used for chronic or pathological pain,” said Dr. Streicher.
The research team tested four terpenes – geraniol, linalool, beta-caryophyllene, and alpha-humulene – on mouse models of post-operative pain and fibromyalgia. All four terpenes showed significant pain relief, with geraniol demonstrating the most potent effect.
“With fibromyalgia, there isn’t much understanding of what the pain state is, and there are not a lot of great options for treating it,” Dr. Streicher explained. “Our findings show that terpenes may be a viable treatment option for fibromyalgia pain, which could potentially have a large impact and make a difference for an under-treated population.”
Fibromyalgia, a chronic musculoskeletal disorder, affects millions worldwide, and post-surgical pain remains a significant challenge, often treated with opioids that can lead to complications. The study suggests that terpenes could offer a safer, non-opioid alternative.
The research also revealed that terpenes act through the adenosine A2a receptor, the same receptor targeted by caffeine, suggesting a potential sedative effect. This mechanism of action was consistent across both post-surgical and fibromyalgia pain models.
The researchers emphasize that this study opens new possibilities for pain management, highlighting the potential of natural compounds.
“The research that is being done by Dr. Streicher’s lab on terpenes and their potential to help those who suffer from chronic pain demonstrates the importance of basic research,” said Dr. Todd Vanderah, director of the Comprehensive Center for Pain & Addiction at the U of A Health Sciences.
The study’s co-authors included Caleb Seekins, Alyssa Welborn, and Abigail Schwarz. Future research will explore the sedative effects of terpenes and further investigate their potential as a therapeutic option.
Disclaimer: This article is based on research findings and should not be interpreted as medical advice. The information provided is for educational purposes only. Individuals experiencing fibromyalgia or post-surgical pain should consult with a qualified healthcare professional before considering any new treatment options. Further research is necessary to confirm these findings in human clinical trials. The use of cannabis-derived products may be subject to legal restrictions depending on local regulations.
